Oramed Pharmaceuticals Inc. [NASDAQ: ORMP] jumped around 1.22 points on Monday, while shares priced at $10.38 at the close of the session, up 13.32%. The company report on March 19, 2021 that Premas Biotech and Oramed Announce Oral COVID-19 Vaccine Candidate That Produces Antibodies After a Single Dose.
Far reaching implications for ease of widescale distribution and administration anytime, anywhere.
Better candidate for protection against COVID-19 variants due to triple antigen targeting.
Oramed Pharmaceuticals Inc. stock is now 144.81% up from its year-to-date (YTD) trading value. ORMP Stock saw the intraday high of $12.10 and lowest of $9.52 per share. The company’s 52-week high price is 11.71, which means current price is +151.94% above from all time high which was touched on 03/22/21.
Compared to the average trading volume of 638.78K shares, ORMP reached a trading volume of 4508102 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Oramed Pharmaceuticals Inc. [ORMP]?
National Securities have made an estimate for Oramed Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on February 09, 2021. While these analysts kept the previous recommendation, Alliance Global Partners raised their target price to Buy. The new note on the price target was released on December 03, 2020, representing the official price target for Oramed Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $5.50, while Aegis Capital analysts kept a Buy rating on ORMP stock.
The Average True Range (ATR) for Oramed Pharmaceuticals Inc. is set at 0.97, with the Price to Sales ratio for ORMP stock in the period of the last 12 months amounting to 104.30. The Price to Book ratio for the last quarter was 8.72, with the Price to Cash per share for the same quarter was set at 1.26.
How has ORMP stock performed recently?
Oramed Pharmaceuticals Inc. [ORMP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 11.97. With this latest performance, ORMP shares dropped by -2.17% in over the last four-week period, additionally plugging by 265.49% over the last 6 months – not to mention a rise of 243.71% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ORMP stock in for the last two-week period is set at 63.16, with the RSI for the last a single of trading hit 66.84, and the three-weeks RSI is set at 62.16 for Oramed Pharmaceuticals Inc. [ORMP]. The present Moving Average for the last 50 days of trading for this stock 8.23, while it was recorded at 9.67 for the last single week of trading, and 4.64 for the last 200 days.
Oramed Pharmaceuticals Inc. [ORMP]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Oramed Pharmaceuticals Inc. [ORMP] shares currently have an operating margin of -433.84. Oramed Pharmaceuticals Inc.’s Net Margin is presently recorded at -424.76.
Return on Total Capital for ORMP is now -44.92, given the latest momentum, and Return on Invested Capital for the company is -44.02. Return on Equity for this stock declined to -44.04, with Return on Assets sitting at -29.03. When it comes to the capital structure of this company, Oramed Pharmaceuticals Inc. [ORMP] has a Total Debt to Total Equity ratio set at 0.23. Additionally, ORMP Total Debt to Total Capital is recorded at 0.23, with Total Debt to Total Assets ending up at 0.17. Long-Term Debt to Equity for the company is recorded at 0.09, with the Long-Term Debt to Total Capital now at 0.09.
Reflecting on the efficiency of the workforce at the company, Oramed Pharmaceuticals Inc. [ORMP] managed to generate an average of -$959,250 per employee.Oramed Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.30 and a Current Ratio set at 6.30.
Earnings analysis for Oramed Pharmaceuticals Inc. [ORMP]
With the latest financial reports released by the company, Oramed Pharmaceuticals Inc. posted -0.21/share EPS, while the average EPS was predicted by analysts to be reported at -0.17/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -23.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ORMP.
Insider trade positions for Oramed Pharmaceuticals Inc. [ORMP]
There are presently around $9 million, or 11.60% of ORMP stock, in the hands of institutional investors. The top three institutional holders of ORMP stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 372,415, which is approximately -20.529% of the company’s market cap and around 13.90% of the total institutional ownership; FRONTIER WEALTH MANAGEMENT LLC, holding 71,900 shares of the stock with an approximate value of $0.66 million in ORMP stocks shares; and BLACKROCK INC., currently with $0.63 million in ORMP stock with ownership of nearly -22.771% of the company’s market capitalization.
Positions in Oramed Pharmaceuticals Inc. stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 15 institutional holders increased their position in Oramed Pharmaceuticals Inc. [NASDAQ:ORMP] by around 92,713 shares. Additionally, 17 investors decreased positions by around 642,102 shares, while 13 investors held positions by with 143,511 shares. The mentioned changes placed institutional holdings at 878,326 shares, according to the latest SEC report filing. ORMP stock had 11 new institutional investments in for a total of 76,387 shares, while 8 institutional investors sold positions of 392,418 shares during the same period.